World's Best Scientists 2026 revealed!
Janet Dancey

Janet Dancey

D-Index & Metrics

Medicine

D-Index
89
Citations
62428
World Ranking
12410
National Ranking
504

Overview

Janet Dancey is affiliated with Queen's University in Canada and has contributed extensively to the field of medical research. Their work primarily focuses on oncology and related subfields, with significant attention to cancer immunotherapy, genomics, diagnostics, and lung cancer treatments.

Their research spans multiple domains within medicine, with notable emphasis on:

  • Oncology
  • Economics and Econometrics
  • Public Health, Environmental and Occupational Health
  • Cancer Research
  • Pulmonary and Respiratory Medicine

Janet Dancey's main topics of investigation include:

  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Health Systems, Economic Evaluations, Quality of Life
  • Ethics in Clinical Research
  • Economic and Financial Impacts of Cancer
  • Lung Cancer Treatments and Mutations
  • Biomedical Ethics and Regulation

The scientist has published multiple papers in notable journals, demonstrating research activity in clinical oncology and health evaluation. Selected recent papers are:

  • Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy, 2023, Journal of Clinical Oncology
  • ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results, 2023, Nature Medicine
  • CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC, 2021, Journal of Thoracic Oncology
  • CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in Canada, 2021, Current Oncology
  • CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC), 2020, Journal of Clinical Oncology

Their work frequently appears in the following publication venues:

  • Journal of Clinical Oncology
  • Current Oncology
  • Journal of Thoracic Oncology
  • UNC Libraries
  • Nature Medicine

Janet Dancey has collaborated extensively with a number of coauthors, including:

  • Scott A. Laurie
  • Stephen Sundquist
  • Keyue Ding
  • Ming-Sound Tsao
  • Valsamo Anagnostou

Best Publications

  • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

    Elizabeth Eisenhauer;Patrick Therasse;Jan Bogaerts;L.H. Schwartz

  • Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

    Frances A. Shepherd;Janet Dancey;Rodryg Ramlau;Karin Mattson

  • iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

    Lesley Seymour;Jan Bogaerts;Andrea Perrone;Robert Ford

  • RECIST 1.1—Update and clarification: From the RECIST committee

    Lawrence H. Schwartz;Lawrence H. Schwartz;Saskia Litiere;Elisabeth G. E. de Vries;Robert Ford

  • Response assessment criteria for brain metastases: proposal from the RANO group

    Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

    Evanthia Galanis;Jan C. Buckner;Matthew J. Maurer;Jeffrey I. Kreisberg

  • Issues and progress with protein kinase inhibitors for cancer treatment

    Janet Dancey;Edward A. Sausville

  • Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Malcolm J. Moore;J. Hamm;J. Dancey;P. D. Eisenberg

  • Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

    Susan M. Chang;Patrick Wen;Timothy Cloughesy;Harry Greenberg

  • mTOR signaling and drug development in cancer

    Janet Dancey

  • Strategies for optimizing combinations of molecularly targeted anticancer agents.

    Janet E. Dancey;Helen X. Chen

  • Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

    Melanie B. Thomas;Romil Chadha;Katrina Glover;Xuemei Wang

  • The Genetic Basis for Cancer Treatment Decisions

    Janet E. Dancey;Philippe L. Bedard;Philippe L. Bedard;Nicole Onetto;Thomas J. Hudson;Thomas J. Hudson

  • Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

    Kamal S. Saini;Kamal S. Saini;Sherene Loi;Evandro de Azambuja;Otto Metzger-Filho

  • A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

    Jeffrey J. Raizer;Lauren E. Abrey;Andrew B. Lassman;Susan M. Chang

  • Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

    Amit M. Oza;Laurie Elit;Ming-Sound Tsao;Suzanne Kamel-Reid

  • A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.

    Duran I;Kortmansky J;Singh D;Hirte H

  • Treatment of Nonresectable Hepatocellular Carcinoma with Intrahepatic 90Y-Microspheres

    Janet E. Dancey;Frances A. Shepherd;Karen Paul;Kenneth W. Sniderman

  • A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

    Ramesh K. Ramanathan;Chandra P. Belani;Deepti A. Singh;Michael Tanaka

Frequent Co-Authors

Patrick Y. Wen
Patrick Y. Wen Harvard University
Susan M. Chang
Susan M. Chang University of California, San Francisco
Michael D. Prados
Michael D. Prados University of California, San Francisco
Lillian L. Siu
Lillian L. Siu University of Toronto
Lincoln Stein
Lincoln Stein Ontario Institute for Cancer Research
John Douglas Mcpherson
John Douglas Mcpherson University of California, Davis
Timothy F. Cloughesy
Timothy F. Cloughesy University of California, Los Angeles
Suzanne Kamel-Reid
Suzanne Kamel-Reid University Health Network
Gregory R. Pond
Gregory R. Pond McMaster University
Thomas J. Hudson
Thomas J. Hudson Ontario Institute for Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medicine, there are a variety of online degrees and career pathways to consider. Many students explore options like nursing, healthcare administration, nutrition, and nurse practitioner roles, all of which play critical parts in the healthcare ecosystem.

If you’re pursuing nursing but want to avoid extensive entrance exams, some may benefit from nursing school that don't require teas. These programs can make the application process more accessible, especially for those balancing other responsibilities.

For those interested in organizational leadership, healthcare administration degree programs offer flexible, accelerated pathways to enter the growing field of healthcare management. These degrees are ideal for future hospital managers, administrators, or policy makers.

Registered nurses looking to specialize further may consider rn to np programs, which provide an efficient route to become a Nurse Practitioner through bridge courses designed for working professionals.

Nutrition is another vital area; there are a wide range of online nutrition degree programs for those passionate about dietetics and wellness. These programs enable students to learn evidence-based strategies for promoting health at individual and community levels.

Best Scientists Citing Janet Dancey

Trending Scientists